Neutralizing #Activity and Viral #Escape of #Pemivibart by #SARS-CoV-2 #JN1 #sublineages
Source: BioRxIV, AbstractPemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing…
#Pemivibart is less active against recent #SARS-CoV-2 #JN1 #sublineages http://biorxiv.org/cgi/content/short/2024.08.12.607496v1?rss=1
Pemivibart neutralized both JN.1 and #KP2 in vitro with comparable activity, whereas its potency was decreased slightly against #LB1, #KP23, and #KP3 but substantially against #KP311. Critically, the 50% inhibitory concentration of pemivibart against KP.3.1.1 was ~6 g/mL, or ~32.7 fold higher than that of JN.1.
#SARSCoV2 #Omicron family quickly swells to 900+ #sublineages!
Add another 203+ recombinant lineages (w/ Omicron partner)
Currently, we are watching "Omicron" Great-Great-Great grand kids.. especially the recombinant families..
Recombinants have outcompeted others globally!
#Omicron family swells to 708+ #sublineages!
add to that another 90+ recombinant Omicron lineages
Currently, we are watching "Omicron" Great-Great-Great grand kids.. especially the recombinant family members
XBB.1.5* will be the dominant lineage in North America soon!
#Omicron family swells to 653+ #sublineages!
Currently, we are watching "Omicron" Great-Great-Great grand kids.. especially the recombinant family members
Expected to outcompete other circulating Omicrons including Omicron-BQ*
XBB.1.5* poised to take over North America soon!
